PMID- 15096322
OWN - NLM
STAT- MEDLINE
DCOM- 20041005
LR  - 20051116
IS  - 0949-2321 (Print)
IS  - 0949-2321 (Linking)
VI  - 9
IP  - 3
DP  - 2004 Mar 30
TI  - Low molecular weight heparins as thromboprophylaxis in patients undergoing 
      hemodialysis/hemofiltration or continuous renal replacement therapies.
PG  - 125-30
AB  - Low molecular weight heparins (LMWHs) have potential advantages over 
      unfractionated heparin (UFH). They interact less with platelets and may induce 
      less bleeding. The risk for heparin induced thrombocytopenia is less, and the 
      effect on serum lipids is favourable. The half-life is longer, allowing for one 
      single bolus dose at start of hemodialysis (HD). In addition, LMWH is found to 
      result in lower plasma potassium in HD patients compared to UFH. LMWHs have an 
      established role in HD and hemofiltration (HF), but the reports on their efficacy 
      and safety during continuous renal replacement therapy (CRRT) are scarce.
FAU - Sagedal, Solbjorg
AU  - Sagedal S
AD  - Department of Medicine, Rikshospitalet University Hospital, N-0027 Oslo, Norway. 
      solbjorg.sagedal@rikshospitalet.no
FAU - Hartmann, Anders
AU  - Hartmann A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Eur J Med Res
JT  - European journal of medical research
JID - 9517857
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - *Hemofiltration
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - *Renal Dialysis
MH  - Thrombosis/physiopathology/*prevention & control
RF  - 45
EDAT- 2004/04/21 05:00
MHDA- 2004/10/06 09:00
CRDT- 2004/04/21 05:00
PHST- 2004/04/21 05:00 [pubmed]
PHST- 2004/10/06 09:00 [medline]
PHST- 2004/04/21 05:00 [entrez]
PST - ppublish
SO  - Eur J Med Res. 2004 Mar 30;9(3):125-30.